Abstract
Following the staggering impact of anti-HER2 treatment in improving the outcomes for breast and gastric cancers, human epidermal growth factor receptor 2 (HER2 neu) has emerged as a promising new oncogenic target for metastatic colorectal carcinoma (mCRC) also. Through this article, we review the role of HER2 in mCRC as a prognostic biormarker as well as a poor predictive factor and mechanism of resistance against anti-EGFR therapy. We discuss the emergence of dual anti-HER2 blockade as effective therapeutic intervention for HER2 amplified mCRC and the advantageous role of ct-DNA in appropriate clinical setting. Furthermore, we explore the encouraging future paradigms for effectively targeting HER2 in mCRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have